ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / PDSB / earnings
CUE (29) ALXO (44) MGNX (24) NGEN (45) ⌘ Pro Terminal →

PDS Biotechnology Corporation (PDSB) Next Earnings Date & Expected ±12.5% Move

$1.37 -4.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.36

PDS Biotechnology Corporation (PDSB) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $151.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PDSB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PDSB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PDS Biotechnology Corporation (NASDAQ: PDSB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.37 (-4.86% 1D, market cap $151.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PDSB ranks #337 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PDSB compare to CUE and ALXO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PDSB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M) and ALXO (ALX Oncology Holdings Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M). Among the 5-stock peer group, PDSB leads on earnings multiple (N/A) while PDSB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PDSB?
▼

Per PDSB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472091), PDS Biotechnology Corporation generated $88.3M in revenue (-13.2% YoY), -$34.5M in net income, and -$27.8M in free cash flow against $30.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.36 (-1.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (15)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE PDSB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PDSB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY PDSB SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$1.60-40% Next Q
Q2 (-2Q)
51
Grade C-$0.96+35.4% Next Q
Q3 (-1Q)
49
Grade D$1.30+5.4% Next Q
Current
46
Grade D$1.37-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PDSB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PDSB currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.85) and Max Pain ($1.44) forces dealer call-delta covering toward $1.88.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PDSB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PDSB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.17 Expected Swing
$1.20 (-12.5%)Spot $1.37$1.54 (+12.5%)
MODEL EARNINGS SETUP GAUGE

PDSB Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (46/100)Model Risk Weight (54/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$88.3M-$34.5M-$27.8M52%
FY 20242024-12-31$101.7M-$37.6M-$35.1M52%
FY 20232023-12-31$120.5M-$42.9M-$33.6M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PDSB)

  • ✓Walkthrough of PDSB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PDSB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.00%📐 HORIZONTAL RANGE
2026-11-03O $1.55H $1.55L $1.37C $1.37VOL 5.55M
RES: $1.88SUP: $-0.49SMA50: $0.85SMA200: $0.83
$1.90$1.44$0.97$0.51$0.05RES $1.88SUP $-0.49$1.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PDSB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PDSB Butterfly Map → + Track PDSB →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PDSB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PDSB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PDSB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PDSB)

Health Care Rank #337 of 1016 ⚔️ CUE vs PDSB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PDSB vs. CUE, ALXO, MGNX, NGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PDS Biotechnology Corporation (PDSB) ranks #337 by composite RQD confidence (46/100, grade D) and #605 by equity capitalization ($151.2M). Within this direct 5-issuer industry benchmark cohort, PDSB leads on earnings valuation at N/A trailing P/E, while PDSB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PDSB currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PDSB ACTIVE
PDS Biotechnology Corporation
D 46/100 — — -35.0% -4.86% $151.2M Benchmark Subject
CUE
Cue Biopharma Inc.
E 29/100 — — -35.0% -6.95% $151.6M /cue-vs-pdsb →
ALXO
ALX Oncology Holdings Inc.
D 44/100 — — -35.0% +12.30% $152.4M /alxo-vs-pdsb →
MGNX
MacroGenics Inc.
E 24/100 — 96.0% -35.0% -2.92% $152.9M /mgnx-vs-pdsb →
NGEN
NervGen Pharma Corp.
D 45/100 — — — -1.46% $147.4M /ngen-vs-pdsb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001472091

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PDS Biotechnology Corporation (PDSB) reported GAAP revenue of $88.3M (-13.2% vs. FY2024 revenue of $101.7M , and -26.7% cumulative change since FY2023) , GAAP net income of -$34.5M, operating cash flow of -$27.8M, and free cash flow of -$27.8M (+20.8% YoY). On the balance sheet, PDSB closed FY2025 with $30.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $88.3M -$34.5M -$27.8M -$27.8M $30.5M —
FY2024 (FY) 2024-12-31 $101.7M -$37.6M -$35.0M -$35.1M $45.4M —
FY2023 (FY) 2023-12-31 $120.5M -$42.9M -$33.6M -$33.6M — —

3. PDSB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PDSB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PDS Biotechnology Corporation (NASDAQ: PDSB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.37 (-4.86% 1D, market cap $151.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PDSB ranks #337 in composite RQD confidence.

How does PDSB compare to CUE and ALXO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PDSB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M) and ALXO (ALX Oncology Holdings Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M). Among the 5-stock peer group, PDSB leads on earnings multiple (N/A) while PDSB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PDSB?

Per PDSB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472091), PDS Biotechnology Corporation generated $88.3M in revenue (-13.2% YoY), -$34.5M in net income, and -$27.8M in free cash flow against $30.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PDSB trading relative to its 50-day, 200-day, and 52-week technical levels?

PDSB last traded at $1.37 (-4.86% on volume of 4,122,539 shares), positioning the stock +61.18% above its 50-day simple moving average ($0.85) and +65.06% above its 200-day simple moving average ($0.83). Across its 52-week range of $0.19 to $1.79, PDSB sits at the 73.8% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

Direct Sub-Reports: PDSB RQD Cockpit PDSB 12M Forecast PDSB Earnings & Move PDSB Dividends & DRIP PDSB Insiders & 13F PDSB Whale Options PDSB Profit Sankey PDSB News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PDSB — PDS Biotechnology Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:42:21Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

PDSB scores 45 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." Pillar scores are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -17.05%), Whale 13F Flow 12/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 12/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, and the strongest relative pillars are Whale 13F Flow and Macro Regime Fit, each at 12/20. The cash engine pillar is the most concerning in absolute terms, given negative ROIC and negative FCF yield. For a prospective investor, the rating indicates that the current profile is weighted toward underperformance and distribution risk rather than cash generation. Any upside case would need to rest on factors outside reported operating economics, such as institutional accumulation or sector-level re-rating, which the rating itself does not treat as sufficient to offset the weaker fundamentals and insider picture. This is an analytical summary, not personalized financial advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

PDS Biotechnology Corporation (PDSB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.

Reported revenue is — across all three listed periods, and operating and net losses are reported in each. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. The Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $41.7M in FY 2024 to $26.7M in FY 2025, while debt is listed as N/A in the source data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case: Whale 13F Flow scores 12/20 on institutional accumulation and options positioning, and the stock trades near the top of its $1.35–$1.69 52-week range at $1.55. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield -17.05%) and Institutional Whale Flow at 15/20, sustained execution supports upside toward the top of the $0.19 – $1.79 52-week range.
  • 🐻 Primary Bear Case: Reported ROIC of -35% and FCF yield of -17.05% alongside FY 2025 FCF of -$27.8M against cash of $26.7M point to ongoing cash burn with limited balance sheet cushion. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the absence of mapped links means this dossier cannot identify ripple effects from partners, suppliers, or customers.

  • Key Question #1: What is the company's cash runway given reported cash of $26.7M against FY 2025 negative FCF of -$27.8M?
  • Key Question #2: Why is debt reported as N/A, and what is the complete capital structure behind the Debt/Equity figure of 0.5?
  • Key Question #3: How sensitive is PDSB's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?

PDSB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PDS Biotechnology Corporation (PDSB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PDSB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PDSB Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PDSB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PDSB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.84 (+27.8%)
📌 Pinned Debate

Whale 13F Flow scores 12/20 on institutional accumulation and options positioning, and the stock trades near the top of its $1.35–$1.69

Picked up a starter position in PDSB in my $100K Virtual Cash book at $1.44. Whale 13F Flow scores 12/20 on institutional accumulation and options positioning, and the stock trades near the top of its $1.35–$1.69 52-week range at $1.55.. Trading inside a $0.26–$1.79 52-week range with -17.05% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 46/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.44 and keeping dry powder in case we test $1.34.

MU MultipleCompression Valuation Discipline 🐻 BEARISH 🎯 Target: $1.20 (-16.7%)
Spot @ $1.44

Reported ROIC of -35% and FCF yield of -17.05% alongside FY 2025 FCF of -$27.8M against cash of $26.7M point to ongoing cash burn with

Reported ROIC of -35% and FCF yield of -17.05% alongside FY 2025 FCF of -$27.8M against cash of $26.7M point to ongoing cash burn with limited balance sheet cushion.. Look at the math on PDSB: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.27 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%